Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2020 Dec 28;15(3):404–415. doi: 10.1007/s11684-021-0834-9

Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection

Weibao Song 1,#, Hongjuan Zhang 1,#, Yu Zhang 1, Rui Li 1, Yanxing Han 1, Yuan Lin 1,✉, Jiandong Jiang 1,✉
PMCID: PMC7768800  PMID: 33369711

Abstract

Zika virus (ZIKV) is an emerging pathogen associated with neurological complications, such as Guillain-Barré syndrome in adults and microcephaly in fetuses and newborns. This mosquito-borne flavivirus causes important social and sanitary problems owing to its rapid dissemination. However, the development of antivirals against ZIKV is lagging. Although various strategies have been used to study anti-ZIKV agents, approved drugs or vaccines for the treatment (or prevention) of ZIKV infections are currently unavailable. Repurposing clinically approved drugs could be an effective approach to quickly respond to an emergency outbreak of ZIKV infections. The well-established safety profiles and optimal dosage of these clinically approved drugs could provide an economical, safe, and efficacious approach to address ZIKV infections. This review focuses on the recent research and development of agents against ZIKV infection by repurposing clinical drugs. Their characteristics, targets, and potential use in anti-ZIKV therapy are presented. This review provides an update and some successful strategies in the search for anti-ZIKV agents are given.

Keywords: Zika virus, clinical drugs, ZIKV inhibitors, antivirals, repurposing

Acknowledgements

This work was supported by CAMS Major Collaborative Innovation Project (No. 2016-I2M-1-011), National Natural Science Foundation of China (No. 81773784), Beijing Nova Program (No. Z181100006218075), Basic Scientific Research Program of CAMS (No. 2018RC350005), and Drug Innovation Major Project (No. 2018ZX09711001-002-002).

Compliance with ethics guidelines

Weibao Song, Hongjuan Zhang, Yu Zhang, Rui Li, Yanxing Han, Yuan Lin, and Jiandong Jiang declare that they have no financial conflicts of interest. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

Footnotes

These authors contributed equally to this work.

Contributor Information

Yuan Lin, Email: linyuan@imm.ac.cn.

Jiandong Jiang, Email: jiang.jdong@163.com.

References

  • 1.Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. 2016;29(3):487–524. doi: 10.1128/CMR.00072-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, Neil J, Ghawché F. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–1539. doi: 10.1016/S0140-6736(16)00562-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Blohm GM, Lednicky JA, Márquez M, White SK, Loeb JC, Pacheco CA, Nolan DJ, Paisie T, Salemi M, Rodríguez-Morales AJ, Glenn Morris J, Jr, Pulliam JRC, Paniz-Mondolfi AE. Evidence for mother-to-child transmission of Zika virus through breast milk. Clin Infect Dis. 2018;66(7):1120–1121. doi: 10.1093/cid/cix968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Heymann DL, Hodgson A, Sall AA, Freedman DO, Staples JE, Althabe F, Baruah K, Mahmud G, Kandun N, Vasconcelos PF, Bino S, Menon KU. Zika virus and microcephaly: why is this situation a PHEIC? Lancet. 2016;387(10020):719–721. doi: 10.1016/S0140-6736(16)00320-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, Guzman H, Tesh RB, Weaver SC. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis. 2012;6(2):e1477. doi: 10.1371/journal.pntd.0001477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sinigaglia A, Riccetti S, Trevisan M, Barzon L. In silico approaches to Zika virus drug discovery. Expert Opin Drug Discov. 2018;13(9):825–835. doi: 10.1080/17460441.2018.1515909. [DOI] [PubMed] [Google Scholar]
  • 7.Baz M, Boivin G. Antiviral agents in development for Zika virus infections. Pharmaceuticals (Basel) 2019;12(3):E101. doi: 10.3390/ph12030101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mastrangelo E, Milani M, Bollati M, Selisko B, Peyrane F, Pandini V, Sorrentino G, Canard B, Konarev PV, Svergun DI, de Lamballerie X, Coutard B, Khromykh AA, Bolognesi M. Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein. J Mol Biol. 2007;372(2):444–455. doi: 10.1016/j.jmb.2007.06.055. [DOI] [PubMed] [Google Scholar]
  • 9.Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science. 2016;353(6298):503–505. doi: 10.1126/science.aag2419. [DOI] [PubMed] [Google Scholar]
  • 10.Zhao B, Yi G, Du F, Chuang YC, Vaughan RC, Sankaran B, Kao CC, Li P. Structure and function of the Zika virus full-length NS5 protein. Nat Commun. 2017;8(1):14762. doi: 10.1038/ncomms14762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Phoo WW, Li Y, Zhang Z, Lee MY, Loh YR, Tan YB, Ng EY, Lescar J, Kang C, Luo D. Structure of the NS2B-NS3 protease from Zika virus after self-cleavage. Nat Commun. 2016;7(1):13410. doi: 10.1038/ncomms13410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Onorati M, Li Z, Liu F, Sousa AMM, Nakagawa N, Li M, Dell’Anno MT, Gulden FO, Pochareddy S, Tebbenkamp ATN, Han W, Pletikos M, Gao T, Zhu Y, Bichsel C, Varela L, Szigeti-Buck K, Lisgo S, Zhang Y, Testen A, Gao XB, Mlakar J, Popovic M, Flamand M, Strittmatter SM, Kaczmarek LK, Anton ES, Horvath TL, Lindenbach BD, Sestan N. Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia. Cell Rep. 2016;16(10):2576–2592. doi: 10.1016/j.celrep.2016.08.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zou J, Shi PY. Strategies for Zika drug discovery. Curr Opin Virol. 2019;35:19–26. doi: 10.1016/j.coviro.2019.01.005. [DOI] [PubMed] [Google Scholar]
  • 14.Shiryaev SA, Farhy C, Pinto A, Huang CT, Simonetti N, Elong Ngono A, Dewing A, Shresta S, Pinkerton AB, Cieplak P, Strongin AY, Terskikh AV. Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res. 2017;143:218–229. doi: 10.1016/j.antiviral.2017.04.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Elfiky AA, Elshemey WM. Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds. J Med Virol. 2018;90(1):13–18. doi: 10.1002/jmv.24934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gadea G, Bos S, Krejbich-Trotot P, Clain E, Viranaicken W, El-Kalamouni C, Mavingui P, Desprès P. A robust method for the rapid generation of recombinant Zika virus expressing the GFP reporter gene. Virology. 2016;497:157–162. doi: 10.1016/j.virol.2016.07.015. [DOI] [PubMed] [Google Scholar]
  • 17.Xie X, Zou J, Shan C, Yang Y, Kum DB, Dallmeier K, Neyts J, Shi PY. Zika virus replicons for drug discovery. EBioMedicine. 2016;12:156–160. doi: 10.1016/j.ebiom.2016.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz G, McGrath EL, Urrabaz-Garza R, Gao J, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe. 2016;20(2):259–270. doi: 10.1016/j.chom.2016.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand KJ, Huang R, Xia M, Ming GL, Zheng W, Song H, Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med. 2016;22(10):1101–1107. doi: 10.1038/nm.4184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP. Zika vaccines and therapeutics: landscape analysis and challenges ahead. BMC Med. 2018;16(1):84. doi: 10.1186/s12916-018-1067-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Diamond MS, Ledgerwood JE, Pierson TC. Zika virus vaccine development: progress in the face of new challenges. Annu Rev Med. 2019;70(1):121–135. doi: 10.1146/annurev-med-040717-051127. [DOI] [PubMed] [Google Scholar]
  • 22.Allison M. NCATS launches drug repurposing program. Nat Biotechnol. 2012;30(7):571–572. doi: 10.1038/nbt0712-571a. [DOI] [PubMed] [Google Scholar]
  • 23.Konreddy AK, Rani GU, Lee K, Choi Y. Recent drug-repurposing-driven advances in the discovery of novel antibiotics. Curr Med Chem. 2019;26(28):5363–5388. doi: 10.2174/0929867325666180706101404. [DOI] [PubMed] [Google Scholar]
  • 24.Dandu K, Kallamadi PR, Thakur SS, Rao CM. Drug repurposing for retinoblastoma: recent advances. Curr Top Med Chem. 2019;19(17):1535–1544. doi: 10.2174/1568026619666190119152706. [DOI] [PubMed] [Google Scholar]
  • 25.Han Y, Mesplède T. Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update. Expert Opin Investig Drugs. 2018;27(12):951–962. doi: 10.1080/13543784.2018.1548609. [DOI] [PubMed] [Google Scholar]
  • 26.Devillers J. Repurposing drugs for use against Zika virus infection. SAR QSAR Environ Res. 2018;29(2):103–115. doi: 10.1080/1062936X.2017.1411642. [DOI] [PubMed] [Google Scholar]
  • 27.Schlitzer M. Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development. ChemMedChem. 2007;2(7):944–986. doi: 10.1002/cmdc.200600240. [DOI] [PubMed] [Google Scholar]
  • 28.Delvecchio R, Higa LM, Pezzuto P, Valadão AL, Garcez PP, Monteiro FL, Loiola EC, Dias AA, Silva FJ, Aliota MT, Caine EA, Osorio JE, Bellio M, O’Connor DH, Rehen S, de Aguiar RS, Savarino A, Campanati L, Tanuri A. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses. 2016;8(12):E322. doi: 10.3390/v8120322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sacramento CQ, de Melo GR, de Freitas CS, Rocha N, Hoelz LV, Miranda M, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G, Abrantes JL, Vieira YR, Bastos MM, de Mello Volotão E, Nunes EP, Tschoeke DA, Leomil L, Loiola EC, Trindade P, Rehen SK, Bozza FA, Bozza PT, Boechat N, Thompson FL, de Filippis AM, Brüning K, Souza TM. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep. 2017;7(1):40920. doi: 10.1038/srep40920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, Qin CF, Li H. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27(8):1046–1064. doi: 10.1038/cr.2017.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov. 2013;12(1):35–50. doi: 10.1038/nrd3913. [DOI] [PubMed] [Google Scholar]
  • 32.Napolitano F, Zhao Y, Moreira VM, Tagliaferri R, Kere J, D’Amato M, Greco D. Drug repositioning: a machine-learning approach through data integration. J Cheminform. 2013;5(1):30. doi: 10.1186/1758-2946-5-30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pujol A, Mosca R, Farrés J, Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci. 2010;31(3):115–123. doi: 10.1016/j.tips.2009.11.006. [DOI] [PubMed] [Google Scholar]
  • 34.Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS, Geiss BJ. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res. 2017;137:134–140. doi: 10.1016/j.antiviral.2016.11.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mehrotra PK, Kitchlu S, Dwivedi A, Agnihotri PK, Srivastava S, Roy R, Bhaduri AP. Emetine ditartrate: a possible lead for emergency contraception. Contraception. 2004;69(5):379–387. doi: 10.1016/j.contraception.2003.12.011. [DOI] [PubMed] [Google Scholar]
  • 36.Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34(5):267–272. doi: 10.1016/j.tips.2013.03.004. [DOI] [PubMed] [Google Scholar]
  • 37.Chopra D, Bhandari B. Sofosbuvir: really meets the unmet needs for hepatitis C treatment? Infect Disord Drug Targets. 2020;20(1):2–15. doi: 10.2174/1871526518666180816101124. [DOI] [PubMed] [Google Scholar]
  • 38.Bhatia HK, Singh H, Grewal N, Natt NK. Sofosbuvir: a novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother. 2014;5(4):278–284. doi: 10.4103/0976-500X.142464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–34347. doi: 10.1074/jbc.M110.161802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Herbst DA, Jr, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert Opin Investig Drugs. 2013;22(4):527–536. doi: 10.1517/13543784.2013.775246. [DOI] [PubMed] [Google Scholar]
  • 41.Liu J, Du J, Wang P, Nagarathnam D, Espiritu CL, Bao H, Murakami E, Furman PA, Sofia MJA. A 2′-deoxy-2′-fluoro-2′-C-methyl uridine cyclopentyl carbocyclic analog and its phosphoramidate prodrug as inhibitors of HCV NS5B polymerase. Nucleosides Nucleotides Nucleic Acids. 2012;31(4):277–285. doi: 10.1080/15257770.2012.658131. [DOI] [PubMed] [Google Scholar]
  • 42.Mumtaz N, Jimmerson LC, Bushman LR, Kiser JJ, Aron G, Reusken CBEM, Koopmans MPG, van Kampen JJA. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res. 2017;146:161–163. doi: 10.1016/j.antiviral.2017.09.004. [DOI] [PubMed] [Google Scholar]
  • 43.Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. J Antimicrob Chemother. 2017;72(3):727–734. doi: 10.1093/jac/dkw514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Matthews H, Usman-Idris M, Khan F, Read M, Nirmalan N. Drug repositioning as a route to anti-malarial drug discovery: preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate. Malar J. 2013;12(1):359. doi: 10.1186/1475-2875-12-359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Krstin S, Mohamed T, Wang X, Wink M. How do the alkaloids emetine and homoharringtonine kill trypanosomes? An insight into their molecular modes of action. Phytomedicine. 2016;23(14):1771–1777. doi: 10.1016/j.phymed.2016.10.008. [DOI] [PubMed] [Google Scholar]
  • 46.Saif M. Treatment of amoebiasis. J Egypt Public Health Assoc. 1973;48(3):159–166. [PubMed] [Google Scholar]
  • 47.Yang S, Xu M, Lee EM, Gorshkov K, Shiryaev SA, He S, Sun W, Cheng YS, Hu X, Tharappel AM, Lu B, Pinto A, Farhy C, Huang CT, Zhang Z, Zhu W, Wu Y, Zhou Y, Song G, Zhu H, Shamim K, Martínez-Romero C, García-Sastre A, Preston RA, Jayaweera DT, Huang R, Huang W, Xia M, Simeonov A, Ming G, Qiu X, Terskikh AV, Tang H, Song H, Zheng W. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov. 2018;4(1):31. doi: 10.1038/s41421-018-0034-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Lin Y, Zhang H, Song W, Si S, Han Y, Jiang J. Identification and characterization of Zika virus NS5 RNA-dependent RNA polymerase inhibitors. Int J Antimicrob Agents. 2019;54(4):502–506. doi: 10.1016/j.ijantimicag.2019.07.010. [DOI] [PubMed] [Google Scholar]
  • 49.Helms S, Miller A. Natural treatment of chronic rhinosinusitis. Altern Med Rev. 2006;11(3):196–207. [PubMed] [Google Scholar]
  • 50.Julander JG, Siddharthan V, Evans J, Taylor R, Tolbert K, Apuli C, Stewart J, Collins P, Gebre M, Neilson S, Van Wettere A, Lee YM, Sheridan WP, Morrey JD, Babu YS. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Res. 2017;137:14–22. doi: 10.1016/j.antiviral.2016.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Munjal A, Khandia R, Dhama K, Sachan S, Karthik K, Tiwari R, Malik YS, Kumar D, Singh RK, Iqbal HMN, Joshi SK. Advances in developing therapies to combat Zika virus: current knowledge and future perspectives. Front Microbiol. 2017;8:1469. doi: 10.3389/fmicb.2017.01469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kumar A, Liang B, Aarthy M, Singh SK, Garg N, Mysorekar IU, Giri R. Hydroxychloroquine inhibits Zika virus NS2B-NS3 protease. ACS Omega. 2018;3(12):18132–18141. doi: 10.1021/acsomega.8b01002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Murray CL, Jones CT, Rice CM. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol. 2008;6(9):699–708. doi: 10.1038/nrmicro1928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Erbel P, Schiering N, D’Arcy A, Renatus M, Kroemer M, Lim SP, Yin Z, Keller TH, Vasudevan SG, Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol. 2006;13(4):372–373. doi: 10.1038/nsmb1073. [DOI] [PubMed] [Google Scholar]
  • 55.Kang C, Keller TH, Luo D. Zika virus protease: an antiviral drug target. Trends Microbiol. 2017;25(10):797–808. doi: 10.1016/j.tim.2017.07.001. [DOI] [PubMed] [Google Scholar]
  • 56.Li Z, Brecher M, Deng YQ, Zhang J, Sakamuru S, Liu B, Huang R, Koetzner CA, Allen CA, Jones SA, Chen H, Zhang NN, Tian M, Gao F, Lin Q, Banavali N, Zhou J, Boles N, Xia M, Kramer LD, Qin CF, Li H. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Res. 2017;27(8):1046–1064. doi: 10.1038/cr.2017.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Yakavets I, Lassalle HP, Scheglmann D, Wiehe A, Zorin V, Bezdetnaya L. Temoporfin-in-cyclodextrin-in-liposome—a new approach for anticancer drug delivery: the optimization of composition. Nanomaterials (Basel) 2018;8(10):E847. doi: 10.3390/nano8100847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103. doi: 10.1016/j.antiviral.2014.07.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Shi Z, Wei J, Deng X, Li S, Qiu Y, Shao D, Li B, Zhang K, Xue F, Wang X, Ma Z. Nitazoxanide inhibits the replication of Japanese encephalitis virus in cultured cells and in a mouse model. Virol J. 2014;11(1):10. doi: 10.1186/1743-422X-11-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Rizk OH, Bekhit MG, Hazzaa AAB, El-Khawass EM, Abdelwahab IA. Synthesis, antibacterial evaluation, and DNA gyrase inhibition profile of some new quinoline hybrids. Arch Pharm (Weinheim) 2019;352(10):e1900086. doi: 10.1002/ardp.201900086. [DOI] [PubMed] [Google Scholar]
  • 61.Yuan S, Chan JF, den-Haan H, Chik KK, Zhang AJ, Chan CC, Poon VK, Yip CC, Mak WW, Zhu Z, Zou Z, Tee KM, Cai JP, Chan KH, de la Peña J, Pérez-Sánchez H, Cerón-Carrasco JP, Yuen KY. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo. Antiviral Res. 2017;145:33–43. doi: 10.1016/j.antiviral.2017.07.007. [DOI] [PubMed] [Google Scholar]
  • 62.Flatman RH, Eustaquio A, Li SM, Heide L, Maxwell A. Structure-activity relationships of aminocoumarin-type gyrase and topoi-somerase IV inhibitors obtained by combinatorial biosynthesis. Antimicrob Agents Chemother. 2006;50(4):1136–1142. doi: 10.1128/AAC.50.4.1136-1142.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Chan JF, Chik KK, Yuan S, Yip CC, Zhu Z, Tee KM, Tsang JO, Chan CC, Poon VK, Lu G, Zhang AJ, Lai KK, Chan KH, Kao RY, Yuen KY. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res. 2017;141:29–37. doi: 10.1016/j.antiviral.2017.02.002. [DOI] [PubMed] [Google Scholar]
  • 64.Ginther OJ, Santos VG, Mir RA, Beg MA. Role of LH in the progesterone increase during the bromocriptine-induced prolactin decrease in heifers. Theriogenology. 2012;78(9):1969–1976. doi: 10.1016/j.theriogenology.2012.08.003. [DOI] [PubMed] [Google Scholar]
  • 65.Li Y, Zhang Z, Phoo WW, Loh YR, Li R, Yang HY, Jansson AE, Hill J, Keller TH, Nacro K, Luo D, Kang C. Structural insights into the inhibition of Zika virus NS2B-NS3 protease by a small-molecule inhibitor. Structure. 2018;26(4):555–564. doi: 10.1016/j.str.2018.02.005. [DOI] [PubMed] [Google Scholar]
  • 66.Geng Y, Kohli L, Klocke BJ, Roth KA. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol. 2010;12(5):473–481. doi: 10.1093/neuonc/nop048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Zhu X, Pan Y, Li Y, Jiang Y, Shang H, Gowda DC, Cui L, Cao Y. Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. Int Immunopharmacol. 2012;13(4):392–397. doi: 10.1016/j.intimp.2012.05.012. [DOI] [PubMed] [Google Scholar]
  • 68.Browning DJ. Hydroxychloroquine and Chloroquine Retinopathy. New York: Springer; 2014. Pharmacology of chloroquine and hydroxychloroquine; pp. 35–63. [Google Scholar]
  • 69.Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses. 1990;6(4):481–489. doi: 10.1089/aid.1990.6.481. [DOI] [PubMed] [Google Scholar]
  • 70.Farias KJ, Machado PR, da Fonseca BA. Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. Scientific World Journal. 2013;2013:282734. doi: 10.1155/2013/282734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Zhu YZ, Xu QQ, Wu DG, Ren H, Zhao P, Lao WG, Wang Y, Tao QY, Qian XJ, Wei YH, Cao MM, Qi ZT. Japanese encephalitis virus enters rat neuroblastoma cells via a pH-dependent, dynamin and caveola-mediated endocytosis pathway. J Virol. 2012;86(24):13407–13422. doi: 10.1128/JVI.00903-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Ooi EE, Chew JS, Loh JP, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J. 2006;3(1):39. doi: 10.1186/1743-422X-3-39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Zhu Y, Lin Y, Liu X, Hu W, Wang Y. Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition. Biochem Biophys Res Commun. 2017;483(1):495–501. doi: 10.1016/j.bbrc.2016.12.116. [DOI] [PubMed] [Google Scholar]
  • 74.Shiryaev SA, Mesci P, Pinto A, Fernandes I, Sheets N, Shresta S, Farhy C, Huang CT, Strongin AY, Muotri AR, Terskikh AV. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep. 2017;7(1):15771. doi: 10.1038/s41598-017-15467-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Han Y, Mesplède T, Xu H, Quan Y, Wainberg MA. The antimalarial drug amodiaquine possesses anti-Zika virus activities. J Med Virol. 2018;90(5):796–802. doi: 10.1002/jmv.25031. [DOI] [PubMed] [Google Scholar]
  • 76.Law I, Ilett KF, Hackett LP, Page-Sharp M, Baiwog F, Gomorrai S, Mueller I, Karunajeewa HA, Davis TM. Transfer of chloroquine and desethylchloroquine across the placenta and into milk in Melanesian mothers. Br J Clin Pharmacol. 2008;65(5):674–679. doi: 10.1111/j.1365-2125.2008.03111.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Ruiz-Irastorza G, Khamashta MA. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus. 2008;17(4):271–273. doi: 10.1177/0961203307086643. [DOI] [PubMed] [Google Scholar]
  • 78.Dörner T. Hydroxychloroquine in SLE: old drug, new perspectives. Nat Rev Rheumatol. 2010;6(1):10–11. doi: 10.1038/nrrheum.2009.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42(2):145–153. doi: 10.1007/s12016-010-8243-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Berliner RW, Earle DP, Jr, Taggart JV, Zubrod CG, Welch WJ, Conan NJ, Bauman E, Scudder ST, Shannon JA. Studies on the chemotherapy of the human malarias; of the human malarias the physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-aminoquinoline. J Clin Invest. 1948;27(3):98–107. doi: 10.1172/JCI101980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Tzekov R. Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. Doc Ophthalmol. 2005;110(1):111–120. doi: 10.1007/s10633-005-7349-6. [DOI] [PubMed] [Google Scholar]
  • 82.Titus EO. Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit. 1989;11(4):369–379. [PubMed] [Google Scholar]
  • 83.O’Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 4-Aminoquinolines—past, present, and future: a chemical perspective. Pharmacol Ther. 1998;77(1):29–58. doi: 10.1016/s0163-7258(97)00084-3. [DOI] [PubMed] [Google Scholar]
  • 84.Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30(4):297–308. doi: 10.1016/j.ijantimicag.2007.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Cao B, Parnell LA, Diamond MS, Mysorekar IU. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med. 2017;214(8):2303–2313. doi: 10.1084/jem.20170957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Kaplan YC, Ozsarfati J, Nickel C, Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(5):835–848. doi: 10.1111/bcp.12872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop. 2004;89(3):351–356. doi: 10.1016/j.actatropica.2003.10.012. [DOI] [PubMed] [Google Scholar]
  • 88.Palmer KJ, Holliday SM, Brogden RN. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45(3):430–475. doi: 10.2165/00003495-199345030-00009. [DOI] [PubMed] [Google Scholar]
  • 89.Liu Y, Chen S, Xue R, Zhao J, Di M. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway. Biochem Biophys Res Commun. 2016;470(2):350–355. doi: 10.1016/j.bbrc.2016.01.046. [DOI] [PubMed] [Google Scholar]
  • 90.Krieger D, Vesenbeckh S, Schönfeld N, Bettermann G, Bauer TT, Rüssmann H, Mauch H. Mefloquine as a potential drug against multidrug-resistant tuberculosis. Eur Respir J. 2015;46(5):1503–1505. doi: 10.1183/13993003.00321-2015. [DOI] [PubMed] [Google Scholar]
  • 91.Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53(5):1840–1849. doi: 10.1128/AAC.01614-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Barbosa-Lima G, Moraes AM, Araújo ADS, da Silva ET, de Freitas CS, Vieira YR, Marttorelli A, Neto JC, Bozza PT, de Souza MVN, Souza TML. 2,8-bis(trifluoromethyl)quinoline analogs show improved anti-Zika virus activity, compared to mefloquine. Eur J Med Chem. 2017;127:334–340. doi: 10.1016/j.ejmech.2016.12.058. [DOI] [PubMed] [Google Scholar]
  • 93.Qiao S, Tao S, Rojo de la Vega M, Park SL, Vonderfecht AA, Jacobs SL, Zhang DD, Wondrak GT. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. Autophagy. 2013;9(12):2087–2102. doi: 10.4161/auto.26506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Zhou T, Tan L, Cederquist GY, Fan Y, Hartley BJ, Mukherjee S, Tomishima M, Brennand KJ, Zhang Q, Schwartz RE, Evans T, Studer L, Chen S. High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit Zika virus infection in fetal-like organoids and adult brain. Cell Stem Cell. 2017;21(2):274–283. doi: 10.1016/j.stem.2017.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Zilbermintz L, Leonardi W, Jeong SY, Sjodt M, McComb R, Ho CL, Retterer C, Gharaibeh D, Zamani R, Soloveva V, Bavari S, Levitin A, West J, Bradley KA, Clubb RT, Cohen SN, Gupta V, Martchenko M. Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting. Sci Rep. 2015;5(1):13476. doi: 10.1038/srep13476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci. 2017;42(2):115–128. [PMC free article] [PubMed] [Google Scholar]
  • 97.Sarkar M, Woodland C, Koren G, Einarson AR. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth. 2006;6(1):18. doi: 10.1186/1471-2393-6-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, Mancia Leon WR, Krencik R, Ullian EM, Spatazza J, Pollen AA, Mandel-Brehm C, Nowakowski TJ, Kriegstein AR, DeRisi JL. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA. 2016;113(50):14408–14413. doi: 10.1073/pnas.1618029113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Ramsey PS, Vaules MB, Vasdev GM, Andrews WW, Ramin KD. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol. 2003;188(3):714–718. doi: 10.1067/mob.2003.141. [DOI] [PubMed] [Google Scholar]
  • 100.Kemp MW, Miura Y, Payne MS, Jobe AH, Kallapur SG, Saito M, Stock SJ, Spiller OB, Ireland DJ, Yaegashi N, Clarke M, Hahne D, Rodger J, Keelan JA, Newnham JP. Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. Antimicrob Agents Chemother. 2014;58(11):6581–6591. doi: 10.1128/AAC.03721-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect. 2007;55(3):205–213. doi: 10.1016/j.jinf.2007.05.180. [DOI] [PubMed] [Google Scholar]
  • 102.Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs. 2004;13(9):1159–1169. doi: 10.1517/13543784.13.9.1159. [DOI] [PubMed] [Google Scholar]
  • 103.Shoemaker DM, Simou J, Roland WE. A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections. Ther Clin Risk Manag. 2006;2(2):169–174. doi: 10.2147/tcrm.2006.2.2.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Dei Cas M, Casagni E, Gambaro V, Cesari E, Roda G. Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1116:38–43. doi: 10.1016/j.jchromb.2019.03.036. [DOI] [PubMed] [Google Scholar]
  • 105.McCall M, Toso C, Emamaullee J, Pawlick R, Edgar R, Davis J, Maciver A, Kin T, Arch R, Shapiro AM. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery. 2011;150(1):48–55. doi: 10.1016/j.surg.2011.02.023. [DOI] [PubMed] [Google Scholar]
  • 106.Haddad JJ. Current opinion on 3-[2-[(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid, an investigational drug targeting caspases and caspase-like proteases: the clinical trials in sight and recent anti-inflammatory advances. Recent Pat Inflamm Allergy Drug Discov. 2013;7(3):229–258. doi: 10.2174/1872213x113079990017. [DOI] [PubMed] [Google Scholar]
  • 107.Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-butylphenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004;309(2):634–640. doi: 10.1124/jpet.103.062034. [DOI] [PubMed] [Google Scholar]
  • 108.Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ. The pancaspase inhibitor emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35(3):953–966. doi: 10.1111/liv.12570. [DOI] [PubMed] [Google Scholar]
  • 109.Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor — a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010;31(9):969–978. doi: 10.1111/j.1365-2036.2010.04264.x. [DOI] [PubMed] [Google Scholar]
  • 110.Duke BO. The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol. Bull World Health Organ. 1968;39(2):157–167. [PMC free article] [PubMed] [Google Scholar]
  • 111.Albulescu IC, Kovacikova K, Tas A, Snijder EJ, van Hemert MJ. Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res. 2017;143:230–236. doi: 10.1016/j.antiviral.2017.04.016. [DOI] [PubMed] [Google Scholar]

Articles from Frontiers of Medicine are provided here courtesy of Nature Publishing Group

RESOURCES